<DOC>
	<DOCNO>NCT01385956</DOCNO>
	<brief_summary>The goal clinical research study learn study drug SOM 230 addition standard therapy gemcitabine shrink slow growth pancreatic cancer . The safety tolerability different dos SOM 230 also study . The participant ' physical state , change size tumor , laboratory finding take on-study help u ( study doctor Moffitt Cancer Center ) decide SOM 230 safe effective .</brief_summary>
	<brief_title>SOM 230 Gemcitabine Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This single-arm , open-label , phase I study combination therapy SOM 230 LAR standard treatment gemcitabine . We utilize staggered , sequential dose-escalation design define maximum tolerate dose ( MTD ) SOM 230 LAR combine standard dos gemcitabine . Cycle define 28 day . Treatment administer outpatient basis . Gemcitabine administer IV infusion . The dose base patient 's actual baseline body weight ; dose recalculated weight change &gt; 10 % baseline . The dose gemcitabine give 30 minute , weekly every 3 week follow 1 week rest period . SOM 230 LAR administer intramuscular dose determine dose schema , every month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Cytologically histologically confirm evidence epithelial cancer ( adenocarcinoma ) exocrine pancreas Metastatic locally advance disease . Patients measurable non measurable disease , per RECIST criterion eligible . Minimum 4 week since major surgery , completion radiation Prior treatment gemcitabine alone 5fluorouracil ( 5FU ) radiation adjuvant therapy allow &gt; 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Life expectancy ≥ 12 week Adequate bone marrow function show : absolute neutrophil count ( ANC ) ≥ 1.0 x 10^9/L , Platelets ≥ 100 x 10^9/L , hemoglobin ( Hgb ) &gt; 9 g/dL Adequate liver function show : serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) , serum transaminase activity ≤ 3 x ULN , exception serum transaminase ( &lt; 5 x ULN ) patient liver metastasis . Adequate renal function show serum creatinine ≤ 1.5 x ULN Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within 14 day administration first study treatment . Women must lactate . Both men WOCBP must advise importance use effective birth control measure course study . Signed informed consent participate study must obtain patient fully inform nature potential risk investigator ( his/her designee ) aid write information . Screening electrocardiogram ( ECG ) time electrocardiogram Q wave end T wave correspond electrical systole [ QT ] correct heart rate ( QTc ) &lt; 450 msec Prior treatment cytotoxic chemotherapy except adjuvant therapy Have undergone major surgery within 4 week prior study enrollment Chronic treatment steroid immunosuppressant drug Should receive immunization attenuate live vaccine study period within 1 week study entry . Untreated brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . Patients uncontrolled diabetes mellitus fast plasma glucose &gt; 1.5 ULN glycosylated hemoglobin ( HbA1c ) &gt; 8 % . Note : At principle investigator 's discretion , noneligible patient rescreened adequate medical therapy institute Patients symptomatic cholelithiasis QT related exclusion criterion : Fridericia Correction Formula ( QTcF ) screen &gt; 450 msec ; History syncope family history idiopathic sudden death ; Sustained clinically significant cardiac arrhythmia ; Risk factor Torsades de Pointes hypokalemia , hypomagnesemia , cardiac failure , clinically significant/symptomatic bradycardia , highgrade atrioventricular ( AV ) block ; Concomitant medication ( ) know prolong QT interval ( patient must drug 2 week eligible ) Patients congestive heart failure [ New York Heart Association ( NYHA ) Class III IV ] , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , clinically significant bradycardia , advanced heart block history acute myocardial infarction within 6 month precede enrollment Known history human immunodeficiency virus ( HIV ) Patients severe and/or uncontrolled medical condition condition could affect participation study : Any active ( acute chronic ) uncontrolled infection/ disorder ; Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study therapy Women pregnant breast feeding , women/men able conceive unwilling practice effective method birth control . ( WOCBP must negative serum pregnancy test within 14 day prior administration pasireotide ) . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . Known hypersensitivity somatostatin analogue component pasireotide octreotide LAR formulation History noncompliance medical regimen Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>combination therapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>epithelial cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>exocrine pancreas</keyword>
</DOC>